Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7

Hu,Shaoyan; Wang,Ying; Wu,Shuiyan; Zhang,Mingying; Pan,Jian; Shen,Hongjie; Qi,Xiaofei; Cen,Jiannong; Chen,Zixing; Shen,Bairong; Chen,Ruihua

doi:10.3892/br.2013.149

Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7

Authors:
- Shaoyan Hu
- Ying Wang
- Shuiyan Wu
- Mingying Zhang
- Jian Pan
- Hongjie Shen
- Xiaofei Qi
- Jiannong Cen
- Zixing Chen
- Bairong Shen
- Ruihua Chen
View Affiliations

Affiliations: Department of Hematology and Oncology, The Children's Hospital of Soochow University, Suzhou, Jiangsu 215003, P.R. China, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Center for Systems Biology, Soochow University, Suzhou, Jiangsu 215006, P.R. China, Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: July 22, 2013 https://doi.org/10.3892/br.2013.149
Pages: 702-706

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a transcription factor, the Wilms' tumor 1 (WT1) gene plays an important role in leukemogenesis. The impact of WT1 gene mutations has been reported in acute myeloid leukemia (AML). However, the number of available studies on the spatial configuration changes following WT1 mutation is limited. In this study, we sequenced the mutation in exon 7 of the WT1 gene in 60 children with newly diagnosed AML and the spatial configuration of WT1 with frameshift mutations in exon 7 was evaluated using the software for homology modeling and optimization of molecular dynamics. Three cases with frameshift mutations in exon 7 were identified (3/60; mutation rate, 5%). one case had a mutation that had been previously described, whereas the remaining two mutations were first described in our study. Of the three cases, one case presented with antecedent myelodysplastic syndrome (MDS) and the remaining two cases exhibited primary resistance to induction chemotherapy. The spatial configuration analysis demonstrated that the three mutations affected the spatial structure of exon 7 and even affected exon 8 compared to its wild‑type. This study demonstrated that the frameshift mutation in exon 7 of the WT1 gene is a poor prognostic factor for children with AML, partly through the spatial configuration changes following frameshift mutations of WT1, which highlights the structure‑based function analysis and may facilitate the elucidation of the pathogenesis underlying WT1 gene mutations.

View Figures

View References

1	King-Underwood L, Renshaw J and Pritchard-Jones K: Mutations in the Wilms' tumor gene WT1 in leukemias. Blood. 87:2171–2179. 1996.
2	Inoue K, Ogawa H, Yamagami T, et al: Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 88:2267–2278. 1996.PubMed/NCBI
3	Inoue K, Sugiyama H, Ogawa H, et al: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 84:3071–3079. 1994.PubMed/NCBI
4	Inoue K, Ogawa H, Sonoda Y, et al: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 89:1405–1412. 1997.PubMed/NCBI
5	Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia. 21:868–876. 2007.PubMed/NCBI
6	Ariyaratana S and Loeb DM: The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 9:1–17. 2007. View Article : Google Scholar : PubMed/NCBI
7	King-Underwood L and Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 91:2961–2968. 1998.
8	Hou HA, Huang TC, Lin LI, et al: WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 115:5222–5231. 2010. View Article : Google Scholar
9	Ho PA, Zeng R, Alonzo TA, et al: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 116:702–710. 2010. View Article : Google Scholar
10	Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al: Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 113:5951–5960. 2009. View Article : Google Scholar : PubMed/NCBI
11	Becker H, Marcucci G, Maharry K, et al: Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116:788–792. 2010. View Article : Google Scholar
12	Little M and Wells C: A clinical overview of WT1 gene mutations. Hum Mutat. 9:209–225. 1997. View Article : Google Scholar : PubMed/NCBI
13	Kaczanowski S and Zielenkiewicz P: Why similar protein sequences encode similar three-dimensional structures? Theor Chem Acc. 125:543–550. 2010. View Article : Google Scholar
14	Subspecialty Group of Hematology Diseases; Society of Pediatrics; Chinese Medical Association; and Editorial Board of Chinese Journal of Pediatrics. Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood. Zhonghua Er Ke Za Zhi. 44:877–878. 2006.(In Chinese).
15	Gaidzik VI, Schlenk RF, Moschny S, et al; German-Austrian AML Study Group. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 113:4505–4511. 2009. View Article : Google Scholar : PubMed/NCBI
16	Stoll R, Lee BM, Debler EW, et al: Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol. 372:1227–1245. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ho PA, Kuhn J, Gerbing RB, et al: WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 29:704–711. 2011. View Article : Google Scholar : PubMed/NCBI
18	Maurer U, Weidmann E, Karakas T, et al: Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34⁺progenitors. Blood. 90:4230–4232. 1997.PubMed/NCBI
19	Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ III and Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res. 55:5386–5389. 1995.PubMed/NCBI
20	Rossetti S, Van Unen L, Touw IP, et al: Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation. Oncogene. 24:5325–5332. 2005. View Article : Google Scholar : PubMed/NCBI